A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

NCT01605825 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Ischemic Stroke

Interventions

DRUG: placebo/dalfampridine-ER
DRUG: dalfampridine-ER/placebo

Sponsor

Acorda Therapeutics